Mosaic Therapeutics

Mosaic Therapeutics is a Cambridge biotech developing targeted combination therapies for cancer.

Its proprietary platform integrates genome-scale CRISPR screening, high-throughput combination drug testing across over 1,300 patient-derived tumour models, and advanced computational analysis to identify synergistic drug combinations and predictive stratification biomarkers.

The company focuses on oncology indications with substantial unmet need where drug combinations can deliver deeper and more durable responses. Mosaic maintains a bespoke research relationship with the Wellcome Sanger Institute.